DEFA14A: Hologic Details Merger Impact on Employee Equity

Hologic, Inc. provides employees with an FAQ detailing the impact of its pending acquisition by Blackstone and TPG on unvested RSUs, stock options, and ESPP, along with general company operations post-merger.

Summary

• Hologic will conduct the Gallup engagement survey in 2026.
• Unvested Restricted Stock Units (RSUs) granted before October 21, 2025, will be cashed out at closing for $76 per share, plus a non-tradable Contingent Value Right (CVR) for up to $3 per share.
• The CVR payments, up to $1.50 each, are contingent on the Breast Health business achieving global revenue goals in fiscal years 2026 and 2027.
• RSUs awarded after October 21, 2025, will convert into unvested cash awards, vesting annually, and will include the $76 upfront price plus any CVR payments.
• Shares currently owned by employees will convert to $76.00 per share in cash and one CVR.
• Stock options with an exercise price less than $76 per share will receive cash equal to the excess of $76 over the exercise price, plus one CVR per share.
• Stock options with an exercise price between $76 and $79 per share will only receive one CVR per share, adjusted for the exercise price.
• Stock options with an exercise price equal to or greater than $79 per share will be canceled for no cash or CVR consideration.
• The Hologic Employee Stock Purchase Plan (ESPP) ceased contributions at the end of the period on December 31, 2025, and will not be offered in calendar year 2026.
• Day-to-day work and remote employee status are generally expected to remain unchanged post-acquisition, with decisions delegated to leadership teams.
• Blackstone and TPG's near-term priorities include driving strong sales momentum, investing in innovation, and maintaining excellent customer relationships.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It provides clarity and details on employee equity payouts, which is positive for those with in-the-money options and RSUs. However, the cessation of the ESPP and the cancellation of out-of-money options are negative. The CVR introduces an element of uncertainty, balancing the overall sentiment.

Positives

• Employees with pre-merger RSUs and in-the-money stock options will receive cash payouts and potential CVR payments, providing liquidity and additional value.
• The acquiring entities, Blackstone and TPG, prioritize continuity in day-to-day operations, strong sales momentum, investment in innovation, and maintaining customer relationships.
• The company plans to conduct the Gallup engagement survey in 2026, indicating a continued focus on employee engagement post-acquisition.

Negatives

• Stock options with an exercise price of $79 or more per share will be canceled without any cash or CVR consideration.
• The Hologic ESPP will not be available in calendar year 2026, ending a benefit for employees.
• Contingent Value Right (CVR) payments are not guaranteed and depend on the achievement of specific global revenue goals for the Breast Health business in fiscal years 2026 and 2027.
• Employees are advised of potential tax implications from the equity payouts and encouraged to seek personal financial advice.

Risks

• The timing, receipt, and terms of required governmental and regulatory approvals could delay or cause the abandonment of the proposed transaction.
• The occurrence of any event, change, or other circumstances could give rise to the termination of the merger agreement.
• Hologic stockholders may not approve the proposed transaction.
• The parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• Disruption of management time from ongoing business operations due to the proposed transaction.
• Any announcements relating to the proposed transaction could have adverse effects on the market price of Hologic's common stock.
• Unexpected costs or expenses resulting from the proposed transaction.
• Litigation relating to the proposed transaction.
• The proposed transaction and its announcement could have an adverse effect on Hologic's ability to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders, and its business generally.
• Holders of the CVRs may receive less-than-anticipated payments with respect to the CVRs after the closing of the proposed transaction.

Future Outlook

Hologic expects continuity in day-to-day operations and remote employee status for most teams post-acquisition. The acquiring firms, Blackstone and TPG, will prioritize driving strong sales momentum, investing in innovation, and maintaining excellent customer relationships. The company plans to conduct a Gallup engagement survey in 2026. Contingent Value Right (CVR) payments are tied to the Breast Health business achieving global revenue goals in fiscal years 2026 and 2027.

Management Comments

• "We will conduct the Gallup engagement survey in 2026."
• "For most teams, we currently expect that day-to-day work will remain unchanged and that decisions about day-to-day operations will be left to our leadership teams."
• "A key near-term priority for Blackstone and TPG will be continuity specifically driving strong sales momentum, investing in innovation, and maintaining excellent customer relationships."

Industry Context

This filing provides internal employee-focused details regarding the mechanics of Hologic's acquisition by private equity firms Blackstone and TPG Capital. It highlights the importance of the Breast Health business segment, as CVR payments are tied to its future revenue performance. The acquisition itself reflects ongoing M&A activity within the medical technology and healthcare sectors, where strategic investments are made to capitalize on specific market segments and innovation potential.

Stakeholder Impact

• **Shareholders (employees):** Will receive $76.00 cash per share and one CVR for each common stock share owned, subject to tax implications.
• **Employees with RSUs:** Pre-merger RSUs will be cashed out at $76 plus CVR; post-merger RSUs convert to unvested cash awards with $76 plus CVR, subject to continued employment.
• **Employees with Stock Options:** Payouts vary based on exercise price; options with exercise price >= $79 will be canceled without consideration.
• **Employees (general):** ESPP will cease in 2026. Day-to-day work and remote status are expected to remain largely unchanged for most teams.
• **Customers, Vendors, Partners:** There is a risk that the transaction could adversely affect relationships with these stakeholders.

Next Steps

• Conduct the Gallup engagement survey in 2026.
• Closing of the merger transaction.
• Potential CVR payments to be made after the close of FY26 and FY27, contingent on Breast Health business global revenue goals.
• Continued vesting of unvested cash awards for RSUs granted after October 21, 2025.
• Employees are encouraged to consult with their personal financial advisors regarding tax implications of the merger payouts.

Key Dates

Keywords

Hologic, Merger, Acquisition, Employee Equity, RSUs, Stock Options, ESPP, Contingent Value Right, Blackstone, TPG Capital, Corporate Governance, Breast Health